476472-56-7 Usage
General Description
2-(4-fluorophenyl)-1-(6-methylpyridine-2-yl)ethanone is a chemical compound with the molecular formula C16H14FNO. 2-(4-FLUOROPHENYL)-1-(6-METHYLPYRIDINE-2-YL)ETHANONE is a ketone derivative, with a fluorine-substituted phenyl group attached to one end of the molecule, and a 6-methylpyridine-2-yl group attached to the other end. It is commonly used in organic synthesis and pharmaceutical research as a building block for more complex compounds. The presence of both a fluoro and a pyridine group makes this molecule of interest for medicinal chemistry, as these moieties can influence the compound's pharmacological properties. Additionally, the presence of a ketone group makes it useful for reactions such as nucleophilic addition and enolate chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 476472-56-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,6,4,7 and 2 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 476472-56:
(8*4)+(7*7)+(6*6)+(5*4)+(4*7)+(3*2)+(2*5)+(1*6)=187
187 % 10 = 7
So 476472-56-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H12FNO/c1-10-3-2-4-13(16-10)14(17)9-11-5-7-12(15)8-6-11/h2-8H,9H2,1H3
476472-56-7Relevant articles and documents
NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS
-
Page 39, (2010/02/06)
-
Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain
Sawyer, J. Scott,Anderson, Bryan D.,Beight, Douglas W.,Campbell, Robert M.,Jones, Michael L.,Herron, David K.,Lampe, John W.,McCowan, Jefferson R.,McMillen, William T.,Mort, Nicholas,Parsons, Stephen,Smith, Edward C. R.,Vieth, Michal,Weir, Leonard C.,Yan, Lei,Zhang, Faming,Yingling, Jonathan M.
, p. 3953 - 3956 (2007/10/03)
Pyrazole-based inhibitors of the transforming growth factor-β type I receptor kinase domain (TβR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TβR-I receptor kinase domain.
